Become A Featured Company

KetamineOne Continues to Build Out Leading North American Presence

Ryan Allway

September 13th, 2021

Psychedelics, Top Story

Ketamine has become a promising mental health therapeutic in recent years. With the FDA’s approval of Spravato, for example, the treatment has the potential to alleviate depressive symptoms in as little as 24 hours — far less time than traditional Selective Serotonin Reuptake Inhibitors or other therapies. And researchers are just beginning to understand and appreciate these effects.

KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (FFT: MY0) (“Ketamine One” or the “Company”) is quickly becoming a North American leader in the space by consolidating medical clinics and establishing itself as a mental health platform.

A Growing Footprint

Ketamine One’s subsidiary, Integrated Rehab and Performance Ltd., which was recently re-branded as IRP Health, announced four new veteran-owned, multidisciplinary clinics in the Comox Valley, Ottawa, Halifax, and Surrey regions. The Comox Valley and Ottawa locations will open in September, while the Halifax and Surrey centers will open by the year’s end.

Ketamine One’s EBITDA targets for 2022. Source: Investor Presentation

More recently, the Company signed two new letters of intent with Illumma to acquire ketamine infusion clinics in Texas, bringing its proposed U.S. footprint to six clinics. The two properties are already leading ketamine infusion practices treating individuals with mental health issues, mood disorders, and chronic pain issues in Austin and Bee Cave, Texas.

“The Illumma team is excited to join forces with KetamineOne as we usher in this new paradigm shift in mental health treatment and care,” said Illumma Founder Dr. Ken Adolph. “Throughout this partnership, we will not only be able to help more people heal their mental health issues like depression, anxiety, and post-traumatic stress disorder.”

Ketamine One operates a network of 16 clinics throughout North America with plans to further consolidate the fragmented industry. In addition to near-term revenue from ketamine infusions, the growing footprint provides an ideal base for when psychedelics become more widely legalized, including psilocybin, MDMA, and other substances.

Beyond Ketamine

Ketamine One aims to become a psychedelics leader over time. With the acquisition of KGK Science, the Company’s contract research division places it at the forefront of premium clinical research with a 24-year history and extensive experience spanning pharmaceuticals, cannabis, and emerging psychedelic treatments.

Psychedelics could become a $7.5B market in short order. Source: DataBridge

Earlier this month, the Company announced a commercial agreement with Cognetivity to deploy its Integrated Cognitive Assessment (“ICA”) tool across Ketamine One’s North American clinics. The mental health assessment tool enables long-term monitoring of cognitive performance in patients that goes above and beyond the typical pen-and-paper-based tests.

“The ICA technology will help Ketamine One improve and standardize both the initial assessment and the ongoing monitoring of patients with features not available in traditional paper-based surveys,” said Ketamine One Interim CEO Adam Deffett. “This tool will enable us to further demonstrate the power of our therapies.”

In addition to the ICA technology, the company has recently invested in virtual reality technologies designed to deepen immersion, promote relaxation, and help manage stress. For instance, OVR Technology’s wellness platform combines the benefits of mindfulness, breathwork, and meditation with next-generation aromatherapy.

Looking Ahead

KetamineOne Capital Limited (NEO: MEDI) (OTC: KONEF) (FFT: MY0) is uniquely positioned to capitalize on the psychedelic revolution. In addition to generating near-term revenue, the Company is leveraging the clinics in its research and development ambitions and could emerge from the psychedelics revolution in a leadership role.

For more information, visit the Company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading